Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Studies (PREMIERE)

Next Previous
Search
Trial Profile

Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Studies (PREMIERE)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 30 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cladribine (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PREMIERE
  • Sponsors EMD Serono; Merck Serono

    • Most Recent Events

    • 27 Feb 2021 Results (n=923) from CLARITY, CLARITY Extension, and ORACLE-MS trials, and the PREMIERE registry assessing effect of age at baseline in cladribine 3.5 mg/kg on levels of lymphocyte subsets, presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2021
    • 28 Nov 2020 Results of pooled analysis (data pooled from CLARITY, CLARITY EXTENSION ORACLE-MS and ONWARD studies ) assessing the development of Cladribine tablets for the treatment of Multiple Sclerosis published in the Drugs
    • 26 May 2020 Results of integrated safety analysis from CLARITY, CLARITY Extension, ORACLE-MS and PREMIERE studies presented at the 6th Congress of the European Academy of Neurology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top